Lineage Cell Therapeutics (LCTX) Q1 2024 Earnings
LCTX·Reported May 9, 2024·After market close
Lineage Cell Therapeutics reported Q1 2024 revenue of $1.4M, beat analyst consensus of $1.4M by $84.0K. Diluted EPS came in at $-0.04, missed the $-0.04 consensus by $0.00.
Revenue
$1.4Mbeat by $84.0K
Consensus: $1.4MDiluted EPS
$-0.04missed by $0.00
Consensus: $-0.04
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Lineage Cell Therapeutics's Q1 2024 earnings report.
Lineage Cell Therapeutics (LCTX) reported Q1 2024 earnings on May 9, 2024 after market close.
Lineage Cell Therapeutics reported revenue of $1.4M and diluted EPS of $-0.04 for Q1 2024.
Revenue beat the consensus estimate of $1.4M by $84.0K. EPS missed the consensus estimate of $-0.04 by $0.00.
You can read the 10-Q periodic report (0000950170-24-056998) directly on SEC EDGAR. The filing index links above go to sec.gov.